CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Other Comprehensive Income	Accumulated Earnings (Deficit)
Beginning balance (in shares) at Dec. 31, 2019		76,637,470
Beginning balance at Dec. 31, 2019	$ (43,010)	$ 8	$ 8,352	$ 0	$ 0	$ (51,370)
Beginning balance (in shares) at Dec. 31, 2019				0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Class A-2 Common Stock to Class A-1 Common Stock (in shares)		1,666,636
Conversion of Class A-2 Common Stock to Class A-1 Common Stock	19,924		19,924
Stock-based compensation	$ 5,538		5,538
Exercise of common stock options (in shares)	359,987	359,987
Exercise of common stock options	$ 839		839
Exercise of warrants (in shares)		510
Exercise of warrants	4		4
Exchange of warrants for common stock (in shares)		5,581,890
Exchange of warrants for common stock	54,471		54,471
Issuance of common stock, net (in shares)		9,133,015
Issuance of common stock, net	90,422	$ 1	90,421
Unrealized gain on investment in convertible notes	93				93
Unrealized gain on interest rate caplets	0
Net income (loss)	(410)					(410)
Ending balance (in shares) at Dec. 31, 2020		93,379,508
Ending balance at Dec. 31, 2020	127,871	$ 9	179,549	$ 0	93	(51,780)
Ending balance (in shares) at Dec. 31, 2020				0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 6,403		6,403
Exercise of common stock options (in shares)	577,719
Repurchase of common stock (in shares)		(701,305)		(701,305)
Repurchase of common stock	$ (8,983)			$ (8,983)
Exercise of stock-based awards (in shares)		732,360
Exercise of stock-based awards	1,704		1,704
Unrealized gain on investment in convertible notes	(93)				(93)
Unrealized gain on interest rate caplets	0
Net income (loss)	31,559					31,559
Ending balance (in shares) at Dec. 31, 2021		93,410,563
Ending balance at Dec. 31, 2021	158,461	$ 9	187,656	$ (8,983)	0	(20,221)
Ending balance (in shares) at Dec. 31, 2021				(701,305)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	$ 6,840		6,840
Exercise of common stock options (in shares)	136,998
Repurchase of common stock (in shares)	(7,643,978)	(7,643,978)		(7,643,978)
Repurchase of common stock	$ (79,003)			$ (79,003)
Reissuance of treasury stock in business combination (in shares)		515,622		515,622
Reissuance of treasury stock in business combination	5,584		(705)	$ 6,289
Exercise of stock-based awards (in shares)		392,183
Exercise of stock-based awards	366		366
Unrealized gain on investment in convertible notes	0
Unrealized gain on interest rate caplets	12,240				12,240
Net income (loss)	74,102					74,102
Ending balance (in shares) at Dec. 31, 2022		86,674,390
Ending balance at Dec. 31, 2022	$ 178,590	$ 9	$ 194,157	$ (81,697)	$ 12,240	$ 53,881
Ending balance (in shares) at Dec. 31, 2022				(7,829,661)